Evidence map›Paper›PMID 33201335›Full record

ArticleInternational journal of health economics and management2021

Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy.

Stéphane Alcenat, François Maréchal, Florence Naegelen

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of health economics and management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stéphane AlcenatUniv. Bourgogne Franche-Comté, CRESE EA3190, 25000, Besançon, France.
François MaréchalUniv. Bourgogne Franche-Comté, CRESE EA3190, 25000, Besançon, France. francois.marechal@univ-fcomte.fr.ORCID http://orcid.org/0000-0001-9905-1753
Florence NaegelenUniv. Bourgogne Franche-Comté, CRESE EA3190, 25000, Besançon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper analyzes the decision of a health authority to implement personalized medicine. We consider a model in which the health authority has three possibilities. It can apply either the same treatment (a standard or a new treatment) to the whole population or implement personalized medicine, i.e., use genetic information to offer the most suitable treatment to each patient. We first characterize the drug reimbursement contract of a firm producing a new treatment with a companion genetic test when the firm can undertake an effort to improve drug quality. Then, we determine the conditions under which personalized medicine should be implemented when this effort is observable and when it is not. Finally, we show how the unobservability of effort affects the conditions under which the health authority implements personalized medicine.

Indexed as

Delivery of Health CareMoralsPrecision MedicineTreatment OutcomeUncertaintyAlgorithmsEconomics, PharmaceuticalGenetic TestingHumansGenetic informationHealthcareMoral hazardOptimal contractsPersonalized medicinePharmacoeconomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.